Nitrogen mustards: mustard gas used first during WWI. Leukopenia and GI ulceration noted in survivors Bondage: crosslinking agents.

Slides:



Advertisements
Similar presentations
Cytidine analogue ALL, AML
Advertisements

Prof J.E.Brown Password: CCL.
Wednesday, February 15th Seth Wander
Anticancer Agents Antibiotics Classification of Antibiotics:
Presenters: Maria Maqsood ξ Sania Munir Cancer Immunotherapy.
Cancer Detection and Diagnosis Early Cancer May Not Have Any symptoms Pap Test Mammograms Blood tests Prostate-specific antigen (PSA) Carcinoembryonic.
 Encompass how some hormones and antihormones are utilized as anticancer therapy  Identify concept of immunomodulation as an anticancer treatment modality.
1 By: Abdulaziz bin saeedan P h.D. Department of Pharmacology E mail: P harmacology – IV PHL-425 Chapter 4: CANCER CHEMOTHERAPY.
Novel Drug Design Modified Megestrol by Group II.
Tumor Therapy with Monoclonal Antibodies
Anticancer and Chemotherapy By: Mohamed Fahad Al-Ajmi.
Cancer Therapy Dr Andrejs Liepins/Science Photo Library.
Basis of Medical Cancer Therapy Rebecca Roylance Senior Lecturer in Medical Oncology.
Pharmacology of Chemotherapy
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
PBL 6 – Lymphoma and leukemia
MBBS Cancer Biology Module 2006 Tumour Vasculature and Therapeutic Strategies Barbara Pedley.
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.
CELLULAR BIOLOGY IN BREAST CANCER JESSE ELLMAN MD SEPT 2010 CLINICAL ASSISTANT PROFESSOR DEPT OB GYN AND WOMENS HEALTH WE MAY BE ENTERING A NEW PHASE.
MICROTEACHING Sanjeev Sharma
Cancer Chemotherapy Topics
Understanding the cell cycle - chemotherapy and beyond
CANCER CHEMOTHERAPY. General Principles of Action of Anticancer Drugs A. Treatment strategies B. Treatment regimens and scheduling C. Problems associated.
Cancer therapy - conventional Surgery Radiotherapy Chemotherapy Adjuvant therapies.
Cancer Drug Classes The classes of drugs currently used in the cancer clinic are  1. DNA Binding Agents (intercalating and alkylating.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Cancer Chemotherapy: Development of Drug Resistance.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.
Bishop and Varmus. We Are Making Quite a Progress in Cancer Detection.
Nanocell: Mechanism of action
Angiogenesis ↓ Metastasis. Angiogenesis--- The process of developing new blood vessels. Cancer cells (probably like all tissues) secrete substances that.
Targeted Therapies - little & large explained Chris Clarke Macmillan Lead Pharmacist LNR Cancer Network.
What is Cancer? Disorder of cell growth and behavior
By: Dr. Abdulaziz Bin Saeedan Ph.D. Department of Pharmacology E mail: P harmacology – IV PHL-425 Chapter 2: CANCER CHEMOTHERAPY:
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Principles of Chemotherapy. Objectives At the completion of this session the participant will be able to: ◦ Define combination chemotherapy ◦ Recognize.
Joseph A. De Soto M.D., Ph.D., F.A.I.C.
Microtubule inhibitors
The Practical Side of Nucleotide Metabolism November 29, 2001.
ONCOLOGY Cytotoxic Agents. ONCOLOGY Cytotoxic agents Selective toxicity based on characteristics that distinguish malignant cells from normal cells Antineoplastic.
Adjuvant systemic therapy in breast cancer Targeted therapies Update R. Paridaens Belgian Breast Meeting
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Cytotoxic Agents.
Basic Science of Surgical Oncology
Antineoplastics 1 February :08 AM.
Cancer Chemotherapy Dr.Azarm.  The goal of cancer treatment is eradication of cancer  If not possible shifts to palliation,amelioration and preservation.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 101 Anticancer Drugs I: Cytotoxic Agents.
Therapy of cancer disease This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and.
Anticancer drugs Specific tumor-targeted therapy, Immunomodulators, Anticancer Vaccines.
Therapy Targeted د. نورس نبيل جعفر أخصائية في علم الأورام طبيبة مشرفة بمشفى ابن النفيس مؤتمر نقابة أطباء سورية العلمي الأول.
Anti Kanker. Cancer is the second leading cause of death Each year there are 2,300,000 deaths in the US: ◦ Heart disease 730,000 ◦ Cancer 530,000 ◦ Cerebrovascular.
Cancer Chemotherapy Part I: General Cancer Chemotherapy Chapter 16; Pages 797 to 815A also Section 16.11: Drug Resistance Folder Title: CxChemoPart1(NoTP)
Feb. 17, 2014 Phase II, Foundation BlockAntineoplastics Faculty of Medicine, Kuwait University Prof. Saghir Akhtar RM 327, Phone: 6342
ANTINEOPLASTIC DRUGS - MOLECULAR TARGETED AGENTS WEEK-9 MR160 Chapter 29 (p ) Chapter 31 (p )
一、general information antineoplastic agents
UNIVERSITY OF LUSAKA CANCER CHEMOTHERAPY.
Clinical and Research Updates in Gynecologic Oncology
Folder Title: CxChemoPart1
Anti- CANCER drugs Dr. Mohammed Abd-Almoneim
Pharmacology of Antineoplastic Agents
Microtubule inhibitors
Anticancer drugs.
Anti-cancer treatment טיפול בסרטן
School of Pharmacy, University of Nizwa
Chemotherapy Day 2.
School of Pharmacy, University of Nizwa
Volume 56, Issue 3, Pages (March 2012)
Nat. Rev. Urol. doi: /nrurol
Cancer Therapy and Nanotechnology
Presentation transcript:

Nitrogen mustards: mustard gas used first during WWI. Leukopenia and GI ulceration noted in survivors Bondage: crosslinking agents

Spontaneous activation of mechlorethamine

Bifunctional crosslinking between G residues in the DNA

Other alkylating agents and intermediates mechlorethamine cyclophosphamide procarbazine carmustine parent compound reactive intermediate

Cyclophosphamide (Cytoxan) requires P450 activation in liver

Cisplatin: chloro to hydroxyl conversion in cell G residue in DNA G H2OH2O

Vaporization: Bleomycin, radiation

Bleomycin chelates iron/catalyzes formation of hydroxyl radicals

Confusion Actinomycin D

Actinomycin D: -intercalates into the DNA duplex -blocks RNA synthesis and DNA replication

Topoisomerase inhibitors  Topo II inhibitors doxorubicin (daunorubicin, idarubicin, etoposide) bind to DNA/topo II complex and prevents re- sealing of DNA breaks made by topo II doxorubicin (daunorubicin, idarubicin, etoposide) bind to DNA/topo II complex and prevents re- sealing of DNA breaks made by topo II also act to inhibit DNA and RNA synthesisalso act to inhibit DNA and RNA synthesis etoposide (similar to above) causes DNA strand breaks and cell deathetoposide (similar to above) causes DNA strand breaks and cell death  Topo I inhibitors camptothecins (irinotecan, topotecan) bind the Topo I/DNA complex and prevent religation camptothecins (irinotecan, topotecan) bind the Topo I/DNA complex and prevent religation

Pharmacogenetics

Starvation for substrates  Methotrexate: inhibitor of human DHFR inhibitor of human DHFR  5-fluorouracil: inhibits thymidylate synthetase and misincorporated into RNA inhibits thymidylate synthetase and misincorporated into RNA

5-FU first--> then MTX = antagonism MTX first--> (hrs) then 5-FU = synergism dUMP dTMP 5-FdUMP thymidinesynthetase FH2 FH4 DHFRMTX5-FU purines/aminoacids purines Methotrexate and 5-fluorouracil

Starvation for substrates  Methotrexate: inhibitor of human DHFR inhibitor of human DHFR  5-fluorouracil: inhibits thymidylate synthetase and misincorporated into RNA inhibits thymidylate synthetase and misincorporated into RNA  6 thioguanine: inhibits purine biosynthesis inhibits purine biosynthesis  cytosine arabinoside, difluorodeoxycytidine (gemcitabine): inhibits DNA polymerase and gets misincorporated inhibits DNA polymerase and gets misincorporated  hydroxyurea: inhibits ribonucleotide reductase and therefore DNA synthesis inhibits ribonucleotide reductase and therefore DNA synthesis

Regulation  Hormone therapy: breast cancer breast cancer prostate cancer prostate cancer ovarian, endometrial cancer ovarian, endometrial cancer

Risk of breast CA in BRCA1/2 carriers  BRCA mutations in about 7% of Caucasian breast CA pts.  BRCAs are tumor suppressor proteins  loss of heterozygosity leads to tumor formation  exercise, normal weight, and child bearing delays onset  other variables (environment?) seem to be speeding onset

BRCA protein function?  BRCA proteins have unique domain structures that bind phosphorylated regulatory proteins  BRCA1 is an E3 ubiquitin ligase that participates in DNA repair and BRCA2 seems to be involved in homologous recombination. Both are required for genomic stability

Position of mutation in BRCA determines risk for breast versus ovarian cancer

Tamoxifen antagonizes estrogen action in breast cancer cells and affects growth factor synthesis  Tamoxifen IGF-1 IGF-1 TGF  TGF  plasminogen activator plasminogen activator laminin receptors laminin receptors TGF  TGF 

Emergence of Immunotherapy Paul Ehrlich (1904) hypothesized that antibodies could be used as ‘magic bullets’ to treat cancer Köhler and Milstein (1979) described a method to develop antibodies with defined specificity Rituximab is approved by FDA in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma Addition of rituximab to standard CHOP chemotherapy provided the first improvement in survival in diffuse large cell lymphoma (2002) in 25 years

Antibodies in Cancer Chemotherapy  Herceptin (trastuzumab) humanized monoclonal antibody against HER2 (human epidermal growth factor receptor 2) humanized monoclonal antibody against HER2 (human epidermal growth factor receptor 2)  Avastin (bevacizumab) humanized monoclonal against VEGF (vascular endothelial growth factor) humanized monoclonal against VEGF (vascular endothelial growth factor)  Cetuximab antibody against the EGF receptor antibody against the EGF receptor

Clinical trial of herceptin

Induction of VEGF and angiogenesis  HIF = hypoxia inducible factor  oxygen dependent proline hydroxylation regulates degradation of HIF-  by proteasome  low oxygen leads to increased HIF and induction of VEGF and other genes

Tumor vasculature regrowth after anti-VEGF therapy stopped?

Avastin (bevacizumab) benefits may not persist

Assembly of tubulin into microtubules Vinca alkaloids (vincristine, vinblastine, vindesine) inhibit polymerization Taxol: binds microtubules and prevents depolymer- ization.

Microtubules do more than just help segregate chromosomes at mitosis: for example, they are involved in vesicle transport in neurons.

Gleevec (imatinib) is a specific inhibitor

Imatinib (Gleevec) highly effective in treatment of CML 5000 pts develop CML each year in US 2.1 billion $ for Novartis

Protein kinase inhibitors on the market and in development

Many new drugs targeted to the EGF and VEGFR pathways FDA Tarceva Avastin

Tarceva (erlotinib) is an EGFR tyrosine kinase inhibitor that also promotes regeneration

HDAC inhibitors:promising

Proteasome inhibitor: Bortezomib  small molecule inhibitor of the 26S proteasome  approved by FDA for relapsed multiple myeloma  one-year survival rate was 80 percent among patients taking bortezomib and 66 percent among patients taking dexamethasone